WHY LATIN AMERICA?
The number of drug candidates entering the clinical development phase continues to increase dramatically, bringing with it an increased competition for what is a finite resource of both patients and investigators.
Considering less “traditional” territories for clinical development programs is now an inescapable reality and it is really no longer feasible to disregard emerging territories. At the same time, these territories can contribute tremendously to virtually any program, not just in terms of aspects such as recruitment, but also of other factors such as timelines, cost and, most importantly, quality.
Latin America continues to boom as a territory for clinical research thanks to the advantages it offers over more “traditional” territories for clinical research, as well as other emerging territories.
WHY LATIN AMERICA?
The number of drug candidates entering the clinical development phase continues to increase dramatically, bringing with it an increased competition for what is a finite resource of both patients and investigators.
Considering less “traditional” territories for clinical development programs is now an inescapable reality and it is really no longer feasible to disregard emerging territories. At the same time, these territories can contribute tremendously to virtually any program, not just in terms of aspects such as recruitment, but also of other factors such as timelines, cost and, most importantly, quality.
Latin America continues to boom as a territory for clinical research thanks to the advantages it offers over more “traditional” territories for clinical research, as well as other emerging territories.
THESE ADVANTAGES INCLUDE:
Large patient populations (relatively treatment naive) concentrated in urban areas.
Highly qualified medical personnel with experience of clinical research.
– Knowledge of ICH-GCP Guidelines.
– Eager to participate in clinical trials.
A tradition of Western Medicine.
Stable and well-established regulatory environments.
Similar disease profiles and epidemiology for many diseases to other developed regions.
Lower costs for conducting trials.
Common Language (2 languages covering >600M people).
Inverse seasonality vs. northern hemisphere providing potential for extending the recruitment window for seasonal disorders.
Large patient populations (relatively treatment naive) concentrated in urban areas.
Highly qualified medical personnel with experience of clinical research.
– Knowledge of ICH-GCP Guidelines.
– Eager to participate in clinical trials.
A tradition of Western Medicine.
Stable and well-established regulatory environments.
Similar disease profiles and epidemiology for many diseases to other developed regions.
Lower costs for conducting trials.
Common Language (2 languages covering >600M people).
Inverse seasonality vs. northern hemisphere providing potential for extending the recruitment window for seasonal disorders.
At the same time, there is great regional variability with regards to the maturity of the clinical research industry across the continent and factors such as cultural aspects, working practices, standard of care and attitude towards clinical research can all have important consequences when it comes to conducting trials in the region.
At the same time, there is great regional variability with regards to the maturity of the clinical research industry across the continent and factors such as cultural aspects, working practices, standard of care and attitude towards clinical research can all have important consequences when it comes to conducting trials in the region.